A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib
Anti-Cancer Drugs, 06/29/2012
Boers–Sonderen MJ et al. – The authors describe a patient with metastatic melanoma (T1N2cM1a) with a BRAF V600E mutation. She is currently being treated with selumetinib 75mg twice daily in a phase I trial and has shown complete response for the past 4years. This case report raises questions regarding treatment schedule, treatment duration and management of adverse events.